SrasV1, Ncbi, Merge, bibRecord, 001421

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.

Identifieur interne : 001421 ( Ncbi/Merge ); précédent : 001420; suivant : 001422

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.

Auteurs : Mi-Fang Liang [République populaire de Chine] ; Run-Lei Du ; Jing-Zhi Liu ; Chuan Li ; Quan-Fu Zhang ; Lu-Lu Han ; Jian-Shi Yu ; Shu-Min Duan ; Xiao-Fang Wang ; Kong-Xing Wu ; Zhao-Hui Xiong ; Qi Jin ; De-Xin Li

Source :

Biomedical and environmental sciences : BES [ 0895-3988 ] ; 2005.

RBID : pubmed:16544518

Descripteurs français

English descriptors

KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Viral (immunology), Chlorocebus aethiops, Humans, Membrane Glycoproteins (immunology), Neutralization Tests, Peptide Library, Protein Binding, Protein Engineering, Recombinant Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Vero Cells, Viral Envelope Proteins (immunology), Viral Matrix Proteins (immunology).
MESH :
- chemical , immunology : Antibodies, Viral, Membrane Glycoproteins, Recombinant Proteins, Viral Envelope Proteins, Viral Matrix Proteins.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Chlorocebus aethiops, Humans, Neutralization Tests, Peptide Library, Protein Binding, Protein Engineering, Spike Glycoprotein, Coronavirus, Vero Cells.

Abstract

To develop a specific SARS virus-targeted antibody preparation for emergent prophylaxis and treatment of SARS virus infection.

PubMed: 16544518

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002307
to stream PubMed, to step Curation: 002307
to stream PubMed, to step Checkpoint: 002523

Links to Exploration step

pubmed:16544518

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.</title>
<author><name sortKey="Liang, Mi Fang" sort="Liang, Mi Fang" uniqKey="Liang M" first="Mi-Fang" last="Liang">Mi-Fang Liang</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention, Beijing 100052, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention, Beijing 100052</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Du, Run Lei" sort="Du, Run Lei" uniqKey="Du R" first="Run-Lei" last="Du">Run-Lei Du</name>
</author>
<author><name sortKey="Liu, Jing Zhi" sort="Liu, Jing Zhi" uniqKey="Liu J" first="Jing-Zhi" last="Liu">Jing-Zhi Liu</name>
</author>
<author><name sortKey="Li, Chuan" sort="Li, Chuan" uniqKey="Li C" first="Chuan" last="Li">Chuan Li</name>
</author>
<author><name sortKey="Zhang, Quan Fu" sort="Zhang, Quan Fu" uniqKey="Zhang Q" first="Quan-Fu" last="Zhang">Quan-Fu Zhang</name>
</author>
<author><name sortKey="Han, Lu Lu" sort="Han, Lu Lu" uniqKey="Han L" first="Lu-Lu" last="Han">Lu-Lu Han</name>
</author>
<author><name sortKey="Yu, Jian Shi" sort="Yu, Jian Shi" uniqKey="Yu J" first="Jian-Shi" last="Yu">Jian-Shi Yu</name>
</author>
<author><name sortKey="Duan, Shu Min" sort="Duan, Shu Min" uniqKey="Duan S" first="Shu-Min" last="Duan">Shu-Min Duan</name>
</author>
<author><name sortKey="Wang, Xiao Fang" sort="Wang, Xiao Fang" uniqKey="Wang X" first="Xiao-Fang" last="Wang">Xiao-Fang Wang</name>
</author>
<author><name sortKey="Wu, Kong Xing" sort="Wu, Kong Xing" uniqKey="Wu K" first="Kong-Xing" last="Wu">Kong-Xing Wu</name>
</author>
<author><name sortKey="Xiong, Zhao Hui" sort="Xiong, Zhao Hui" uniqKey="Xiong Z" first="Zhao-Hui" last="Xiong">Zhao-Hui Xiong</name>
</author>
<author><name sortKey="Jin, Qi" sort="Jin, Qi" uniqKey="Jin Q" first="Qi" last="Jin">Qi Jin</name>
</author>
<author><name sortKey="Li, De Xin" sort="Li, De Xin" uniqKey="Li D" first="De-Xin" last="Li">De-Xin Li</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16544518</idno>
<idno type="pmid">16544518</idno>
<idno type="wicri:Area/PubMed/Corpus">002307</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002307</idno>
<idno type="wicri:Area/PubMed/Curation">002307</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002307</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002523</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002523</idno>
<idno type="wicri:Area/Ncbi/Merge">001421</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.</title>
<author><name sortKey="Liang, Mi Fang" sort="Liang, Mi Fang" uniqKey="Liang M" first="Mi-Fang" last="Liang">Mi-Fang Liang</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention, Beijing 100052, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention, Beijing 100052</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Du, Run Lei" sort="Du, Run Lei" uniqKey="Du R" first="Run-Lei" last="Du">Run-Lei Du</name>
</author>
<author><name sortKey="Liu, Jing Zhi" sort="Liu, Jing Zhi" uniqKey="Liu J" first="Jing-Zhi" last="Liu">Jing-Zhi Liu</name>
</author>
<author><name sortKey="Li, Chuan" sort="Li, Chuan" uniqKey="Li C" first="Chuan" last="Li">Chuan Li</name>
</author>
<author><name sortKey="Zhang, Quan Fu" sort="Zhang, Quan Fu" uniqKey="Zhang Q" first="Quan-Fu" last="Zhang">Quan-Fu Zhang</name>
</author>
<author><name sortKey="Han, Lu Lu" sort="Han, Lu Lu" uniqKey="Han L" first="Lu-Lu" last="Han">Lu-Lu Han</name>
</author>
<author><name sortKey="Yu, Jian Shi" sort="Yu, Jian Shi" uniqKey="Yu J" first="Jian-Shi" last="Yu">Jian-Shi Yu</name>
</author>
<author><name sortKey="Duan, Shu Min" sort="Duan, Shu Min" uniqKey="Duan S" first="Shu-Min" last="Duan">Shu-Min Duan</name>
</author>
<author><name sortKey="Wang, Xiao Fang" sort="Wang, Xiao Fang" uniqKey="Wang X" first="Xiao-Fang" last="Wang">Xiao-Fang Wang</name>
</author>
<author><name sortKey="Wu, Kong Xing" sort="Wu, Kong Xing" uniqKey="Wu K" first="Kong-Xing" last="Wu">Kong-Xing Wu</name>
</author>
<author><name sortKey="Xiong, Zhao Hui" sort="Xiong, Zhao Hui" uniqKey="Xiong Z" first="Zhao-Hui" last="Xiong">Zhao-Hui Xiong</name>
</author>
<author><name sortKey="Jin, Qi" sort="Jin, Qi" uniqKey="Jin Q" first="Qi" last="Jin">Qi Jin</name>
</author>
<author><name sortKey="Li, De Xin" sort="Li, De Xin" uniqKey="Li D" first="De-Xin" last="Li">De-Xin Li</name>
</author>
</analytic>
<series><title level="j">Biomedical and environmental sciences : BES</title>
<idno type="ISSN">0895-3988</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Neutralization Tests</term>
<term>Peptide Library</term>
<term>Protein Binding</term>
<term>Protein Engineering</term>
<term>Recombinant Proteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vero Cells</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Matrix Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Banque de peptides</term>
<term>Cellules Vero</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Ingénierie des protéines</term>
<term>Liaison aux protéines</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Protéines de la matrice virale (immunologie)</term>
<term>Protéines recombinantes (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Séquence d'acides aminés</term>
<term>Tests de neutralisation</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Membrane Glycoproteins</term>
<term>Recombinant Proteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Matrix Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Protéines de la matrice virale</term>
<term>Protéines recombinantes</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Neutralization Tests</term>
<term>Peptide Library</term>
<term>Protein Binding</term>
<term>Protein Engineering</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Banque de peptides</term>
<term>Cellules Vero</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Humains</term>
<term>Ingénierie des protéines</term>
<term>Liaison aux protéines</term>
<term>Séquence d'acides aminés</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To develop a specific SARS virus-targeted antibody preparation for emergent prophylaxis and treatment of SARS virus infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16544518</PMID>
<DateCompleted><Year>2006</Year>
<Month>05</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-3988</ISSN>
<JournalIssue CitedMedium="Print"><Volume>18</Volume>
<Issue>6</Issue>
<PubDate><Year>2005</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Biomedical and environmental sciences : BES</Title>
<ISOAbbreviation>Biomed. Environ. Sci.</ISOAbbreviation>
</Journal>
<ArticleTitle>SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.</ArticleTitle>
<Pagination><MedlinePgn>363-74</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To develop a specific SARS virus-targeted antibody preparation for emergent prophylaxis and treatment of SARS virus infection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">By using phage display technology, we constructed a naive antibody library from convalescent SARS patient lymphocytes. To obtain the neutralizing antibody to SARS virus surface proteins, the library panning procedure was performed on purified SARS virions and the specific Fab antibody clones were enriched by four rounds of repeated panning procedure and screened by highthroughput selection. The selected Fab antibodies expressed in the periplasma of E. coli were soluble and further purified and tested for their binding properties and antiviral function to SARS virus. The functional Fab antibodies were converted to full human IgG antibodies with recombinant baculovirus/insect cell systems and their neutralizing activities were further determined.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">After four rounds of the panning, a number of SARS-CoV virus-targeted human recombinant Fab antibodies were isolated from the SARS patient antibody library. Most of these were identified to recognize both natural and recombinant SARS spike (S) proteins, two Fab antibodies were specific for the virus membrane (M) protein, only one bound to SARS-CoV nucleocapsid protein. The SARS-CoV S and M protein-targeted Fab or IgG antibodies showed significant neutralizing activities in cytopathic effect (CPE) inhibition neutralization test, these antibodies were able to completely neutralize the SARS virus and protect the Vero cells from CPE after virus infection. However, the N protein-targeted Fab or IgG antibodies failed to neutralize the virus. In addition, the SARS N protein-targeted human Fab antibody reacted with the denatured N proteins, whereas none of the S and M protein specific neutralizing antibodies did. These results suggested that the S and M protein-specific neutralizing antibodies could recognize conformational epitopes which might be involved in the binding of virions to cellular receptors and the fusion activity of the virus.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The SARS-CoV spike protein and membrane proteins are able to elicite efficient neutralizing antibodies in SARS patients. The neutralizing antibodies we generated in this study may be more promising candidates for prophylaxis and treatment of SARS infection.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Mi-Fang</ForeName>
<Initials>MF</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory for Infectious Disease Control and Prevention, Institute for Viral Disease Control and Prevention, Beijing 100052, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Run-Lei</ForeName>
<Initials>RL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Jing-Zhi</ForeName>
<Initials>JZ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Chuan</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Quan-Fu</ForeName>
<Initials>QF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Lu-Lu</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Jian-Shi</ForeName>
<Initials>JS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Duan</LastName>
<ForeName>Shu-Min</ForeName>
<Initials>SM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Xiao-Fang</ForeName>
<Initials>XF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Kong-Xing</ForeName>
<Initials>KX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xiong</LastName>
<ForeName>Zhao-Hui</ForeName>
<Initials>ZH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Qi</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>De-Xin</ForeName>
<Initials>DX</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Biomed Environ Sci</MedlineTA>
<NlmUniqueID>8909524</NlmUniqueID>
<ISSNLinking>0895-3988</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019151">Peptide Library</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>108502-71-2</RegistryNumber>
<NameOfSubstance UI="C067997">M protein, Coronavirus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019151" MajorTopicYN="N">Peptide Library</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015202" MajorTopicYN="N">Protein Engineering</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>5</Month>
<Day>18</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>3</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16544518</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Du, Run Lei" sort="Du, Run Lei" uniqKey="Du R" first="Run-Lei" last="Du">Run-Lei Du</name>
<name sortKey="Duan, Shu Min" sort="Duan, Shu Min" uniqKey="Duan S" first="Shu-Min" last="Duan">Shu-Min Duan</name>
<name sortKey="Han, Lu Lu" sort="Han, Lu Lu" uniqKey="Han L" first="Lu-Lu" last="Han">Lu-Lu Han</name>
<name sortKey="Jin, Qi" sort="Jin, Qi" uniqKey="Jin Q" first="Qi" last="Jin">Qi Jin</name>
<name sortKey="Li, Chuan" sort="Li, Chuan" uniqKey="Li C" first="Chuan" last="Li">Chuan Li</name>
<name sortKey="Li, De Xin" sort="Li, De Xin" uniqKey="Li D" first="De-Xin" last="Li">De-Xin Li</name>
<name sortKey="Liu, Jing Zhi" sort="Liu, Jing Zhi" uniqKey="Liu J" first="Jing-Zhi" last="Liu">Jing-Zhi Liu</name>
<name sortKey="Wang, Xiao Fang" sort="Wang, Xiao Fang" uniqKey="Wang X" first="Xiao-Fang" last="Wang">Xiao-Fang Wang</name>
<name sortKey="Wu, Kong Xing" sort="Wu, Kong Xing" uniqKey="Wu K" first="Kong-Xing" last="Wu">Kong-Xing Wu</name>
<name sortKey="Xiong, Zhao Hui" sort="Xiong, Zhao Hui" uniqKey="Xiong Z" first="Zhao-Hui" last="Xiong">Zhao-Hui Xiong</name>
<name sortKey="Yu, Jian Shi" sort="Yu, Jian Shi" uniqKey="Yu J" first="Jian-Shi" last="Yu">Jian-Shi Yu</name>
<name sortKey="Zhang, Quan Fu" sort="Zhang, Quan Fu" uniqKey="Zhang Q" first="Quan-Fu" last="Zhang">Quan-Fu Zhang</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Liang, Mi Fang" sort="Liang, Mi Fang" uniqKey="Liang M" first="Mi-Fang" last="Liang">Mi-Fang Liang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001421 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001421 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:16544518
   |texte=   SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:16544518" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki